We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...

Cencora, Inc. COR is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Wells Fargo analyst Stephen Baxter maintained a Hold rating on Cencora (COR – Research Report) yesterday and set a price target of $251.00. The ...

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wells Fargo analyst Stephen Baxter raised the firm’s price target on Cencora (COR) to $251 from $237 and keeps an Equal Weight rating on the ...

Analysts have recently evaluated Cencora and provided 12-month price targets. The average target is $281.67, accompanied by a ...

Cencora, Inc. (NYSE:COR – Get Free Report)’s share price reached a new 52-week high on Monday after JPMorgan Chase & Co.

Harrow's "Harrow Cares" program, in partnership with Cencora, aims to improve access and affordability of eye care treatments ...

Buying $100 In COR: If an investor had bought $100 of COR stock 10 years ago, it would be worth $510.85 today based on a price of $256.50 for COR at the time of writing.

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Shares of Cencora (COR) have been strong performers lately, with the stock up 13.4% over the past month. The stock hit a new 52-week high of $256.81 in the previous session. Cencora has gained 13. ...